Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Molecularly-Driven Doublet Therapy for All Children With Refractory or Recurrent CNS Malignant Neoplasms and Young Adults With Refractory or Recurrent SHH Medulloblastoma

Trial Profile

Molecularly-Driven Doublet Therapy for All Children With Refractory or Recurrent CNS Malignant Neoplasms and Young Adults With Refractory or Recurrent SHH Medulloblastoma

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 09 Jan 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Gemcitabine (Primary) ; Ribociclib (Primary) ; Sonidegib (Primary) ; Trametinib (Primary) ; Filgrastim; Pegfilgrastim
  • Indications Anaplastic astrocytoma; Brain cancer; CNS cancer; Ependymoma; Glioblastoma; Glioma; Medulloblastoma; Oligodendroglioma
  • Focus Adverse reactions; Pharmacokinetics
  • Acronyms SJDAWN
  • Most Recent Events

    • 01 Mar 2018 Status changed from not yet recruiting to recruiting.
    • 20 Feb 2018 Planned initiation date changed from 1 Apr 2023 to 1 Mar 2018.
    • 19 Feb 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top